Transcatheter Technologies GmbH is a privately held medical device company founded in 2009 and headquartered in Regensburg, Germany. Its core product, Trinity, is a third‑generation TAVI system comprised of a bovine pericardium valve with a porcine pericardium sealing cuff mounted on a self‑expanding Nitinol frame and pre‑mounted on a detachable catheter tip. Trinity is designed for controlled positioning and true repositioning after full implantation, with a novel sealing cuff intended to reduce paravalvular leak (PVL) and supra‑annular positioning the company says mitigates atrio‑ventricular (AV) block. The company reported successful six‑month follow‑up results from a pilot study; the principal investigator described the results as striking and highlighted outstanding sealing without PVL. Trinity also uses a "Zero Pressure Crimping" process to protect the valve during folding, which the company expects will improve durability and broaden the procedure's applicability. Financially, Transcatheter Technologies has closed a second tranche of a Series B cash financing and the CEO said he will seek additional investors and potential corporate partners at the TVT 2014 meeting. Transcatheter Technologies is developing TRINITY, a proprietary system for transcatheter aortic valve implantation that pairs a novel anchoring mechanism with a delivery catheter to enable accurate positioning. The valve can be repositioned after full evaluation of function without foreshortening of the prosthesis frame. The valve is pre-mounted on a detachable tip to simplify catheter system assembly in the operating room. The company is led by CEO Dr. Wolfgang Goetz and CTO Hou-Sen Lim and was incorporated in 2009. Transcatheter Technologies closed a Series B to fund near-term clinical plans and intends to use the capital to enter clinical trials later this year. Transcatheter Technologies develops the TRINITY system, a fully repositionable transcatheter aortic heart valve prosthesis and implantation system. The TRINITY technology integrates an anchoring mechanism with a delivery catheter to enable precise positioning of the valve prosthesis. The company intends to use the Series A proceeds to technically validate the TRINITY technology. In conjunction with the financing, industry executives were added to the company’s advisory board to support development and commercialization efforts. The company is led by CEO and cardiac surgeon Dr. Wolfgang Goetz. Transcatheter Technologies was incorporated in 2009 and is based in Regensburg, Germany.

Total raised

$6M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2013